Oseltamivir-related Derealization and Depersonalization Experiences

克流感相關之失去現實、自我感

10.29478/TJP.201009.0010

紀美宏(Mei-Hung Chi)；張惠華(Hui-Hua Chang)；陳柏熹(Po-See Chen)

克流感 ； 失去現實感 ； H1N1新型流感 ； 失去自我感 ； derealization ； depersonalization ； novel influenza A H1N1 ； oseltamivir

台灣精神醫學

24卷3期（2010 / 09 / 01）

232 - 235

英文

目的：日本曾報告多起兒童流感個案，使用克流感後出現神經精神症狀，甚至有致死危險。但克流感與神經精神症狀之相關性及機轉仍未釐清。病例報告：一位有注意力缺失過動的十三歲台灣男孩在出現流感症狀經篩檢為甲型流感後開始克流感治療。服藥一天後病人出現失去現實及自我感之症狀。症狀在停用克流感五天後逐漸消失。結論：流感病人服用克流感後罕有失去現實、自我感的症狀。此個案以Naranjo scale評估，其神經精神症狀「可能」由克流感引起。克流感相關神經精神症狀之高異質性、致病機轉、及辨識高風險病人之方法值得更進一步的研究。

Background: Neuropsychiatric events have been reported in novel influenza A (H1N1) patients treated with oseltamivir, especially in pediatric population, and mostly in Japan. Some of these events may have lethal consequences. Case Report: A 13-year-old boy with attention-deficit/hyperactivity disorder had novel influenza A (H1N1) infection and received oseltamivir treatment. He developed depersonalization and derealization experiences soon after oseltamivir use, which led to functional impairment that persisted for around 10 days. The experiences lasted five days after his stopping of oseltamivir and recovering from the infection. The patient returned to his baseline subsequently. Conclusion: Depersonalization and derealization are uncommon neuropsychiatric manifestations occurred after taking oseltamivir medication in patients with influenza infection. A possible causal relationship according to the Naranjo probability scale was observed. The varied neuropsychiatric adverse events, unclear pathological mechanism, and the approach to identify patients in a high-risk population necessitate further investigation.

1. Li, C.Y.,Yu, Q.,Ye, Z.Q.(2007).A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir.Cell Res,17,357-62.
2. Long, M.(2007).Side effects of Tamiflu: clues from an Asian single nucleotide polymorphism.Cell Res,17,309-10.
3. Maxwell, S.R.(2007).Tamiflu and neuropsychiatric disturbance in adolescents.BMJ,334,1232-3.
4. McNicholl, I.R.,McNicholl, J.J.(2001).Neuraminidase inhibitors: zanamivir and oseltamivir.Ann Pharmacother,35,57-70.
5. Naranjo, C.A.,Busto, U.,Sellers, E.M.(1981).A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther,30,239-45.
6. Terada, K.,Kawai, Y.,Monju, A.,Wakabayashi, T.,Ouchi, K.(2008).Adolescent jump case in Japan associated with influenza but not oseltamivir.Pediatr Infect Dis J,27,88-9.
7. Toovey, S.,Rayner, C.,Prinssen, E.(2008).Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review.Drug Saf,31,1097-114.
8. Wada, T.,Morishima, T.,Okumura, A.(2009).Differences in clinical manifestations of influenza-associated encephalopathy by age.Microbiol Immunol,53,83-8.
9. Yorifuji, T.,Suzuki, E.,Tsuda, T.(2009).Oseltamivir and abnormal behaviors: true or not?.Epidemiology,20,619-21.
10. Yoshino, T.,Nisijima, K.,Shioda, K.,Yui, K.,Kato, S.(2008).Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex.Neurosci Lett,438,67-9.